Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Org Lett ; 8(2): 257-60, 2006 Jan 19.
Artigo em Inglês | MEDLINE | ID: mdl-16408889

RESUMO

[reaction: see text] A series of new dispiro[fluorene-9',6,9' ',12-indeno[1,2b]fluorenes] (DSFIFs) that combine indenofluorene (IF) and spirobifluorene (SBF) architectural specificities have been prepared. Their anodic oxidations lead to the formation of nonsoluble transparent polymers. The photophysical and electrochemical properties of these new molecules have been evaluated for further blue OLED applications.

2.
J Med Chem ; 59(5): 1869-79, 2016 Mar 10.
Artigo em Inglês | MEDLINE | ID: mdl-26878150

RESUMO

A 256-compound library was evaluated in an anti-HIV screen to identify structural "mimics" of the fused tetracyclic indole compound 1 (IDC16) that conserve its anti-HIV activity without associated cytotoxicity. Four diheteroarylamide-type compounds, containing a common 5-nitroisobenzothiazole motif, were identified as active. In subsequent screens, the most potent compound 9 (1C8) was active against wild-type HIV-1IIIB (subtype B, X4-tropic) and HIV-1 97USSN54 (subtype A, R5-tropic) with EC50's of 0.6 and 0.9 µM, respectively. Compound 9 also inhibited HIV strains resistant to drugs targeting HIV reverse transcriptase, protease, integrase, and coreceptor CCR5 with EC50's ranging from 0.9 to 1.5 µM. The CC50 value obtained in a cytotoxicity assay for compound 9 was >100 µM, corresponding to a therapeutic index (CC50/EC50) of approximately 100. Further comparison studies revealed that, whereas the anti-HIV activity for compound 9 and the parent molecule 1 are similar, the cytotoxic effect for compound 9 was, as planned, markedly suppressed.


Assuntos
Processamento Alternativo/efeitos dos fármacos , Fármacos Anti-HIV/farmacologia , Benzotiazóis/farmacologia , HIV-1/efeitos dos fármacos , HIV-1/crescimento & desenvolvimento , Piridonas/farmacologia , Precursores de RNA/metabolismo , RNA Viral/metabolismo , Replicação Viral/efeitos dos fármacos , Processamento Alternativo/genética , Fármacos Anti-HIV/química , Benzotiazóis/síntese química , Benzotiazóis/química , Morte Celular/efeitos dos fármacos , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Transcriptase Reversa do HIV/metabolismo , HIV-1/genética , Humanos , Integrases/metabolismo , Estrutura Molecular , Peptídeo Hidrolases/metabolismo , Piridonas/síntese química , Piridonas/química , Precursores de RNA/genética , RNA Viral/genética , Receptores CXCR5/antagonistas & inibidores , Relação Estrutura-Atividade
3.
Chem Commun (Camb) ; (18): 2280-1, 2003 Sep 21.
Artigo em Inglês | MEDLINE | ID: mdl-14518874

RESUMO

Thermal decomposition of hindered amine-borane adducts leads in high yields to monomeric (dialkylamino)boranes R1R2N-BH2 (R1 and R2 = alkyl) that are new and efficient boron-sources in the Pd0 catalyzed borylation reaction affording monomeric aryl(dialkylamino)boranes R1R2N-BHR3 (R3 = aryl).

4.
Chemistry ; 13(36): 10055-69, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-18022969

RESUMO

A series of new dispiro[fluorene-9',6,9'',12-indeno[1,2b]fluorenes] (DSF-IFs) has been synthesised. These new building blocks for blue-light-emitting devices and electroactive polymers combine indenofluorene (IF) and spirobifluorene (SBF) properties. We report here our synthetic investigations towards these new structures and their thermal, structural, photophysical and electrochemical properties. These properties have been compared to those of IF and SBF. We also report the anodic oxidation of DSF-IFs that leads to the formation of non-soluble transparent three-dimensional polymers. The structural and electrochemical behaviour of these polymers has been studied. The first application of these building blocks as new blue-light-emitting materials in organic light-emitting diodes (OLED) is also reported.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA